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Abstract
Glycosylation of immunoglobulin G (IgG) influences IgG effector function by modulating binding to Fc receptors. To identify genetic
loci associated with IgG glycosylation, we quantitated N-linked IgG glycans using two approaches. After isolating IgG from human
plasma, we performed 77 quantitative measurements of N-glycosylation using ultra-performance liquid chromatography (UPLC) in
2,247 individuals from four European discovery populations. In parallel, we measured IgG N-glycans using MALDI-TOF mass
spectrometry (MS) in a replication cohort of 1,848 Europeans. Meta-analysis of genome-wide association study (GWAS) results
identified 9 genome-wide significant loci (P,2.2761029) in the discovery analysis and two of the same loci (B4GALT1 and MGAT3) in
the replication cohort. Four loci contained genes encoding glycosyltransferases (ST6GAL1, B4GALT1, FUT8, and MGAT3), while the
remaining 5 contained genes that have not been previously implicated in protein glycosylation (IKZF1, IL6ST-ANKRD55, ABCF2-
SMARCD3, SUV420H1, and SMARCB1-DERL3). However, most of them have been strongly associated with autoimmune and
inflammatory conditions (e.g., systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, Crohn’s disease, diabetes type 1,
multiple sclerosis, Graves’ disease, celiac disease, nodular sclerosis) and/or haematological cancers (acute lymphoblastic leukaemia,
Hodgkin lymphoma, and multiple myeloma). Follow-up functional experiments in haplodeficient Ikzf1 knock-out mice showed the
same general pattern of changes in IgG glycosylation as identified in the meta-analysis. As IKZF1 was associated with multiple IgG N-
glycan traits, we explored biomarker potential of affected N-glycans in 101 cases with SLE and 183 matched controls and
demonstrated substantial discriminative power in a ROC-curve analysis (area under the curve = 0.842). Our study shows that it is
possible to identify new loci that control glycosylation of a single plasma protein using GWAS. The results may also provide an
explanation for the reported pleiotropy and antagonistic effects of loci involved in autoimmune diseases and haematological cancer.
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Introduction
Glycosylation is a ubiquitous post-translational protein modifi-
cation that modulates the structure and function of polypeptide
components of glycoproteins [1,2]. N-glycan structures are
essential for multicellular life [3]. Mutations in genes involved in
modification of glycan antennae are common and can lead to
severe or fatal diseases [4]. Variation in protein glycosylation also
has physiological significance, with immunoglobulin G (IgG) being
a well-documented example. Each heavy chain of IgG carries a
single covalently attached bi-antennary N-glycan at the highly
conserved asparagine 297 residue in each of the CH2 domains of
the Fc region of the molecule. The attached oligosaccharides are
structurally important for the stability of the antibody and its
effector functions [5]. In addition, some 15–20% of normal IgG
molecules have complex bi-antennary oligosaccharides in the
variable regions of light or heavy chains [6,7]. 36 different glycans
(Figure 1) can be attached to the conserved Asn297 of the IgG
heavy chain [8,9], leading to hundreds of different IgG isomers
that can be generated from this single glycosylation site.
Glycosylation of IgG has important regulatory functions. The
absence of galactose residues in association with rheumatoid
arthritis was reported nearly 30 years ago [10]. The addition of
sialic acid dramatically changes the physiological role of IgGs,
converting them from pro-inflammatory to anti-inflammatory
agents [11,12]. Addition of fucose to the glycan core interferes
with the binding of IgG to FccRIIIa and greatly diminishes its
capacity for antibody dependent cell-mediated cytotoxicity
(ADCC) [13,14]. Structural analysis of the IgG-Fc/FccRIIIa
complex has demonstrated that specific glycans on FccRIIIa are
also essential for this effect of core-fucose [15] and that removal of
core fucose from IgG glycans increases clinical efficacy of
monoclonal antibodies, enhancing their therapeutic effect through
ADCC mediated killing [16–18].
New high-throughput technologies, such as high/ultra perfor-
mance liquid chromatography (HPLC/UPLC), MALDI-TOF
mass spectrometry (MS) and capillary electrophoresis (CE), allow
us to quantitate N-linked glycans from individual human plasma
proteins. Recently, we performed the first population-based study
to demonstrate physiological variation in IgG glycosylation in
three European founder populations [19]. Using UPLC, we
showed exceptionally high individual variability in glycosylation of
a single protein - human IgG - and substantial heritability of the
observed measurements [19]. In parallel, we quantitated IgG N-
glycans in another European population (Leiden Longevity Study
– LLS) by mass spectrometry. In this study, we combined those
high-throughput glycomics measurements with high-throughput
genomics to perform the first genome wide association (GWA)
study of the human IgG N-glycome.
Results
Genome-wide association study and meta-analysis
We separated a single protein (IgG) from human plasma and
quantitated its N-linked glycans using two state-of-the-art technol-
ogies (UPLC and MALDI-TOF MS). Their comparative advan-
tages in GWA studies were difficult to predict prior to the
conducted analyses, so both were used - one in each available
cohort. We performed 77 quantitative measurements of IgG N-
glycosylation using ultra performance liquid chromatography
(UPLC) in 2247 individuals from four European discovery
populations (CROATIA-Vis, CROATIA-Korcula, ORCADES,
NSPHS). In parallel, we measured IgG N-glycans using MALDI-
TOF mass spectrometry (MS) in 1848 individuals from another
European population (Leiden Longevity Study (LLS)). Descrip-
tions of these population cohorts are found in Table S11. Aiming
to identify genetic loci involved in IgG glycosylation, we
performed a GWA study in both cohorts. Associations at 9 loci
reached genome-wide significance (P,2.2761029) in the discov-
ery meta-analysis and at two loci in the replication cohort. The
two loci identified in the latter cohort were associated with the
analogous glycan traits in the former cohort as detailed in the
subsection ‘‘Replication of our findings’’. Both UPLC and MS
methods for quantitation of N-glycans were found to be amenable
to GWA studies. Since our UPLC study gave a considerably
greater yield of significant findings in comparison to MS study, the
majority of our results section focuses on the findings from the
discovery population cohort, which was studied using the UPLC
method.
Among the nine loci that passed the genome-wide significance
threshold, four contained genes encoding glycosyltransferases
(ST6GAL1, B4GALT1, FUT8 and MGAT3), while the remaining
five loci contained genes that have not been implicated in protein
glycosylation previously (IKZF1, IL6ST-ANKRD55, ABCF2-
SMARCD3, SUV420H1-CHKA and SMARCB1-DERL3). As a rule,
the implicated genes were associated with several N-glycan traits.
The explanation and notation of the 77 N-glycan measures is
presented in Table S1. It comprises 23 directly measured
quantitative IgG glycosylation traits (shown in Figure 1) and 54
derived traits. Descriptive statistics of these measures in the
discovery cohorts are presented in Table S2. GWA analysis was
performed in each of the populations separately and the results
were combined in an inverse-variance weighted meta-analysis.
Summary data for each gene region showing genome-wide
association (p,27.261029) or found to be strongly suggestive
(2.2761029,p,561028) are presented in Table 1. Summary
data for all single-nucleotide polymorphisms (SNPs) and traits with
suggestive associations (p,161025) are presented in Table S3,
with population-specific and pooled genomic control (GC) factors
reported in Table S4.
The most statistically significant association was observed in a
region on chromosome 3 containing the gene ST6GAL1 (Table 1,
Figure S1A). ST6GAL1 codes for the enzyme sialyltransferase 6
which adds sialic acid to various glycoproteins including IgG
glycans (Figure 2), and is therefore a highly biologically plausible
candidate. In this region of about 70 kilobases (kb) we identified
37genome-wide significant SNPs associated with 14 different IgG
glycosylation traits, generally reflecting sialylation of different
glycan structures (Table 1). The strongest association was observed
for the percentage of monosialylation of fucosylated digalactosy-
lated structures in total IgG glycans (IGP29, see Figure 1 and
Table S1 for notation), for which a SNP rs11710456 explained
17%, 16%, 18% and 3% of the trait variation for CROATIA-Vis,
Genetic Loci Affecting IgG Glycosylation
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CROATIA-Korcula, ORCADES and NSPHS respectively (meta-
analysis p = 6.12610275). NSPHS had a very small sample size in
this analysis (N = 179) and may not provide an accurate portrayal
of the variance explained in this particular population (estimated
as 3%). Although the allele frequency is similar between all
populations, in the forest plot (Figure S1A) although NSPHS does
overlap with the other populations, the 95% CI is much larger. It
is also possible that there are population-specific genetic and/or
environmental differences in NSPHS that are affecting the amount
of variance explained by this SNP. After analysis conditioning on
the top SNP (rs11710456) in this region, the SNP rs7652995 still
reached genome-wide significance (p = 4.15610213). After adjust-
ing for this additional SNP, the association peak was completely
removed. This suggests that there are several genetic factors
underlying this association. Conditional analysis of all other
significant and suggestive regions resulted in the complete removal
of the association peak.
We also identified 28 SNPs showing genome-wide significant
associations with 11 IgG glycosylation traits (2.70610211,
p,4.7361028) at a locus on chromosome 9 spanning over
60 kb (Figure S1B). This region includes B4GALT1, which codes
for the galactosyltransferase responsible for the addition of
galactose to IgG glycans (Figure 2). The glycan traits showing
genome-wide association included the percentage of FA2G2S1 in
the total fraction (IGP17), the percentage of FA2G2 in the total
and neutral fraction (IGP13, IGP53), the percentage of sialylation
of fucosylated structures without bisecting GlcNAc (IGP24,
IGP26), the percentage of digalactosylated structures in the total
neutral fraction (IGP57) and, in the opposite direction, the
percentage of bisecting GlcNAc in fucosylated sialylated structures
(IGP36–IGP40).
Figure 1. Structures of glycans separated by HILIC-UPLC analysis of the IgG glycome.
doi:10.1371/journal.pgen.1003225.g001
Author Summary
After analysing glycans attached to human immunoglob-
ulin G in 4,095 individuals, we performed the first genome-
wide association study (GWAS) of the glycome of an
individual protein. Nine genetic loci were found to
associate with glycans with genome-wide significance. Of
these, four were enzymes that directly participate in IgG
glycosylation, thus the observed associations were biolog-
ically founded. The remaining five genetic loci were not
previously implicated in protein glycosylation, but the
most of them have been reported to be relevant for
autoimmune and inflammatory conditions and/or haema-
tological cancers. A particularly interesting gene, IKZF1 was
found to be associated with multiple IgG N-glycans. This
gene has been implicated in numerous diseases, including
systemic lupus erythematosus (SLE). We analysed N-
glycans in 101 cases with SLE and 183 matched controls
and demonstrated their substantial biomarker potential.
Our study shows that it is possible to identify new loci that
control glycosylation of a single plasma protein using
GWAS. Our results may also provide an explanation for
opposite effects of some genes in autoimmune diseases
and haematological cancer.
Genetic Loci Affecting IgG Glycosylation
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A large (541 kb) region on chromosome 14 harbouring the
FUT8 gene contained 167 SNPs showing significant associations
with 12 IgG glycosylation traits reflecting fucosylation of IgG
glycans (Figure S1C). FUT8 codes for fucosyltransferase 8, an
enzyme responsible for the addition of fucose to IgG glycans
(Figure 2). The strongest association (1.08610222,p,
2.60610217) was observed with the percentage of A2 glycans in
total and neutral fractions (IGP2, IGP42) and for derived traits
related to the proportion of fucosylation (IGP58, IGP59 and
IGP61; all in the opposite direction). In summary, SNPs at the
FUT8 locus influence the proportion of fucosylated glycans, and,
in the opposite direction, the percentages of A2, A2G1 and A2G2
glycans which are not fucosylated.
On chromosome 22, two loci were associated with IgG
glycosylation. The first region, containing SYNGR1-TAB1-
MGAT3-CACNA1I genes, spans over 233 kb. This region har-
boured 60 SNPs showing genome-wide significant association with
17 IgG glycosylation traits (Figure S1D). Association was strongest
between SNP rs909674 and the incidence of bisecting GlcNAc in
all fucosylated disialylated structures (IGP40, p = 9.66610225) and
the related ratio IGP39 (p = 8.87610224). In summary, this locus
contained variants influencing levels of fucosylated species and the
ratio between fucosylated (especially disialylated) structures with
and without bisecting GlcNAc (Figure 2). Since MGAT3 codes for
the enzyme N-acetylglucosaminyltransferase III (beta-1,4-manno-
syl-glycoprotein-4-beta-N-acetylglucosaminyltransferase), which is
responsible for the addition of bisecting GlcNAc to IgG glycans,
this gene is the most biologically plausible candidate.
Bioinformatic analysis of known and predicted protein-protein
interactions using String 9.0 software (http://string-db.org/)
showed that interactions between the clusters of FUT8-
B4GALT1-MGAT3 genes and ST6GAL1-B4GALT1-MGAT3 genes
had high confidence score: FUT8-B4GALT1 of 0.90; FUT8-
MGAT3 of 0.95; ST6GAL1-B4GALT1 of 0.90; and ST6GAL1-
Figure 2. A summary of changes to IgG N-glycan structures that were associated with 16 loci identified through GWA study.
doi:10.1371/journal.pgen.1003225.g002
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MGAT3 of 0.73. The glycosyltranferase genes at the four GWAS
loci - ST6GAL1, B4GALT1, FUT8, and MGAT3 – are responsible
for adding sialic acid, galactose, fucose and bisecting GlcNAc to
IgG glycans, thus demonstrating the proof of principle that a single
protein glycosylation GWAS approach can identify biologically
important glycan pathways and their networks. Interestingly,
ST6GAL1 has been previously associated with Type 2 diabetes
[20], MGAT3 with Crohn’s disease [21], primary biliary cirrhosis
[22] and cardiac arrest [23], and FUT8 with multiple sclerosis,
blood glutamate levels [24] and conduct disorder [25] (Table 2).
We have recently shown changes in plasma N-glycan profile
between patients with attention-deficit hyperactivity disorder
(ADHD), autism spectrum disorders and healthy controls, and
identified loci influencing plasma N-glycome with pleiotropic
effects on ADHD [26,27].
Novel candidate genes involved with N-glycosylation
In addition to four loci containing genes for enzymes known to
be involved in IgG glycosylation, our study also found five
unexpected associations showing genome-wide significance. In the
second region on chromosome 22 we observed genome-wide
significant associations of 10 SNPs with 20 IgG glycosylation traits.
The region spans 49 kb and contains the genes SMARCB1-DERL3
(Figure S1E). The strongest associations (8.63610217,p,
3.00610213) were observed between SNP rs2186369 and the
percentage of FA2[6]BG1 in total and neutral fractions (IGP9,
IGP49) and levels of fucosylated structures with bisecting GlcNAc
(IGP66, IGP68, IGP70, IGP71 in the same direction and IGP72
in the opposite direction). Thus, the SMARCB1-DERL3 locus
appears to specifically influence levels of fucosylated monogalac-
tosylated structures with bisecting GlcNAc (Figure 2). DERL3 is a
promising functional candidate, because it encodes a functional
component of endoplasmic reticulum (ER)-associated degradation
for misfolded luminal glycoproteins [28]. However, SMARCB1 is
also known to be important in antiviral activity, inhibition of
tumour formation, neurodevelopment, cell proliferation and
differentiation [29]. The region has also been implicated in the
regulation of c-glutamyl-transferase (GGT) [30] (Table 2).
A locus on chromosome 7 spanning 26kb contained 11 SNPs
showing genome-wide significant associations with 13 IgG
glycosylation traits (Figure S1F). The strongest association
(p = 1.87610213) was observed between SNP rs6421315 located
in IKZF1 and the percentage of fucosylation of agalactosylated
structures without bisecting GlcNAc (IGP63). Thus, SNPs at this
locus influence the percentage of non-fucosylated agalactosylated
glycans, the fucosylation ratio in agalactosylated glycans (in
opposite directions for glycan species with and without bisecting
GlcNAc), and the ratio of fucosylated structures with and without
bisecting GlcNAc (Figure 2). The IKZF1 gene encodes the DNA-
binding protein Ikaros, acting as a transcriptional regulator and
associated with chromatin remodelling. It is considered to be the
important regulator of lymphocyte differentiation and has been
shown to influence effector pathways through control of class
switch recombination [31], thus representing a promising func-
tional candidate [32]. There is overwhelming evidence that IKZF1
variants are associated with childhood acute lymphoblastic
leukaemia [33,34] and several diseases with an autoimmune
component: systemic lupus erythematosus (SLE) [35–37], type 1
diabetes [38,39], Crohn’s disease [40], systemic sclerosis [41],
malaria [42] and erythrocyte mean corpuscular volume [43]
(Table 2).
SNPs at several other loci also showed genome-wide significant
association with a number of different IgG glycosylation traits
(Figure S1G–S1P). Chromosome 5 SNP rs17348299, located in
IL6ST-ANKRD55 was significantly associated (6.88610211,p,
2.3961029) with six IgG glycosylation traits, including FA2 and
FA2G2 in total and neutral fractions (IGP3, IGP13, IGP43,
IGP53) and the percentage of agalactosylated and digalactosylated
structures in total neutral IgG glycans (IGP55, IGP57) (Figure 2).
The protein encoded by IL6ST is a signal transducer shared by
many cytokines, including interleukin 6 (IL6), ciliary neurotrophic
factor (CNTF), leukaemia inhibitory factor (LIF), and oncostatin
M (OSM). Variants in IL6ST have been associated with
rheumatoid arthritis and multiple myeloma, but also with
components of metabolic syndrome [44–46].
The chromosome 7 SNP rs2072209 located in LAMB1 was
strongly suggestively associated with the percentage of fucosylation
of digalactosylated (with bisecting GlcNAc) structures (IGP69;
p = 1.1661028) (Figure 2). LAMB1 (laminin beta 1) is a member of
a family of extracellular matrix glycoproteins that are the major
non-collagenous constituent of basement membranes. It is thought
to mediate the attachment, migration and organization of cells
into tissues during embryonic development by interacting with
other extracellular matrix components. It has been associated with
ulcerative colitis in several large-scale studies in European and
Japanese populations, suggesting that changes in the integrity of
the intestinal epithelial barrier may contribute to the pathogenesis
of the disease [47–51] (Table 2).
Another particularly interesting finding was the suggestive
association between rs404256 in the BACH2 gene on chromosome
6 and IGP7, defined through proportional contribution of
FA2[6]G1 in all IgG glycans (p = 7.4961029). BACH2 is B-cell-
specific transcription factor that can act as a suppressor or
promoter; among many known functions, it has been shown to
‘‘orchestrate’’ transcriptional activation of B-cells, modify the
cytotoxic effects of anticancer drugs and regulate IL-2 expression
in umbilical cord blood CD4+ T cells [52]. BACH2 has been
previously associated with a spectrum of diseases with autoimmune
component: type 1 diabetes [53–56], Graves’ disease [57], celiac
disease [58], Crohn’s disease [21] and multiple sclerosis [59]
(Table 2).
The chromosome 11 SNP rs4930561 located in the SUV420H1-
CHKA gene was associated with percentage of FA1 in neutral
(IGP41; p = 8.88610210) and total (IGP1; p = 1.3061028) frac-
tions of IgG glycans. SUV420H1 codes for histone-lysine N-
methyltransferase which specifically trimethylates lysine 20 of
histone H4 and could therefore affect activity of many different
genes; it is thought to be involved in proviral silencing in somatic
and germ line cells through epigenetic mechanisms [60]. CHKA
has a key role in phospholipid biosynthesis and may contribute to
tumour cell growth. We recently reported a number of strong
associations between lipidomics and glycomics traits in human
plasma [61]. Thus, an enzyme involved in phospholipid synthesis
is also a possible candidate because the lipid environment is known
to affect glycosyltransferases activity [61].
Three further loci were identified as strongly suggestive through
GWAS and deserve attention for their possible pleiotropic effects.
SNP rs9296009 in PRRT1 (proline-rich transmembrane protein 1)
was associated with IGP23 (p = 3.79610208) while variants in
PRRT1 previously showed associations with nodular sclerosis and
Hodgkin lymphoma [62]. Moreover, rs1049110 in HLA-DQA2-
HLA-DQB2 was associated with IGP2 and IGP42 (p = 1.64610208
and 4.44610208, respectively). This SNP is in nearly complete
linkage disequilibrium with two other SNPs in this region that have
previously been associated with SLE and hepatitis B [63] (Table 2).
Another SNP in this region has been linked with narcolepsy [64].
Finally, rs7224668 in SLC38A10, a putative sodium-dependent
amino acid/proton antiporter, showed significant association with
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IGP31 (p = 3.33610208). Although the function of this gene is not
understood, it has been associated with autism and longevity
[65,66].
The remaining three signals implicated ABCF2-SMARCD3 region
(rs1122979 was associated with IGP 2, 5, 42, 45, with p-value
ranging between 2.10610210,p,1.8961029), RECK (rs4878639
was suggestively associated with IGP17; p = 3.5161028) and PEX5
(rs12828421 suggestively associated with IGP41; p = 4.4861028).
The function of ABCF2 (ATP-binding cassette, sub-family F,
member 2) is not well understood. SMARCD3 stimulates nuclear
receptor mediated transcription; it belongs to the neural progen-
itors-specific chromatin remodelling complex (npBAF complex) and
the neuron-specific chromatin-remodelling complex (nBAF com-
plex). RECK is known to be a strong suppressor of tumour invasion
and metastasis, regulating metalloproteinases which are involved in
cancer progression. PEX 5 binds to the C-terminal PTS1-type
tripeptide peroxisomal targeting signal and plays an essential role in
peroxisomal protein import (www.genecards.org).
Results from an independent cohort using MS
quantitation method
The parallel effort in the outbred Leiden Longevity Study (LLS)
was based on a different N-glycan quantitation method (MS). While
UPLC groups glycans according to structural similarities, MS groups
them by mass. Furthermore, MS analysis focused on Fc glycans
while UPLC measures both Fc and Fab glycans, thus traits measured
by the two methods could not have been directly compared.
Glycosylation patterns of IgG1 and IgG2 were investigated by
analysis of tryptic glycopeptides, with six glycoforms per IgG subclass
measured. The intensities of all glycoforms were related to the
monogalactosylated, core-fucosylated biantennary species, providing
five relative intensities registered per IgG subclass (Tables S5 and
S6). The analysis identified two loci as genome-wide significant -
implicating MGAT3 (p = 1.6610210 for G1FN, analogous to UPLC
IGP9; p = 3.1261028 for G0FN, analogous to UPLC IGP5), and
B4GALT1 (p = 5.461028 for G2F, analogous to UPLC IGP13)
confirming GWAS signals in the discovery meta-analysis.
Replication of our findings
We then sought a separate independent replication of the other
14 genome-wide significant and strongly suggestive signals
identified in the discovery analysis, which was performed in the
LLS cohort, appreciating that the quantitated N-glycan traits do
not exactly match between the two cohorts. SNPs were chosen for
replication based on initial meta-analysis results of genotype data
prior to imputed analysis. All five traits measured in LLS cohort
were tested for association with all the selected SNPs (Table S6).
We were able to reproduce association to ST6GAL1 (p = 8.161027
for G2F, substrate for sialyltransferase) and SMARCB1-DERL3
(p = 1.661027 for G1N, analogous to UPLC IGP9). Weaker,
though nominally significant associations were confirmed at IKZF1
(p = 2.361023 for G1N), SLC38A10 (p = 4.861023 for G2N),
IL6ST-ANKRD55 (p = 1.361022 for G0N) and ABCF2-SMARCD3
(p = 2.761022 for G2N). The fact that we did not replicate
associations at the other 8 loci was not unexpected, because those
8 loci showed association with UPLC-measured N-glycan traits
that do not compare to any of the traits measured by MS (see
Table S5 for comparison of MS and UPLC traits).
Functional experiment: Ikzf1 haplodeficiency results in
altered N-glycosylation of IgG
IKZF1 is considered to be the important regulator governing
differentiation of T cells into CD4+ and CD8+ T cells [67].
Since glycan traits associated with IKZF1 were related to the
presence and absence of core-fucose and bisecting GlcNAc, we
analysed the promoter region of MGAT3 (codes for enzyme that
adds bisecting GlcNAc to IgG glycans) in silico and identified two
binding sites for IKZF1 that were conserved between humans
and mice, while recognition sites for IKZF1 were not found in the
promoter region of FUT8 (which codes for an enzyme that adds
core-fucose to IgG glycans). Since the promoter regions of
MGAT3 were conserved between humans and mice, we used
Ikzf1 knockout mice [68] as a model to study the effects of IKZF1
deficiency on IgG glycosylation. IgG was isolated from the
plasma of 5 heterozygous knockout mice and 5 wild-type
controls. The summary of the results of IgG glycosylation
analysis is presented in Table 3, while complete results are
presented in Table S7. We observed a number of alterations in
glycome composition that were all consistent with the role of
IKZF1 in the down-regulation of fucosylation and up-regulation
of the addition of bisecting GlcNAc to IgG glycans; 12 out of 77
IgG N-glycans measures showed statistically significant differ-
ence (p,0.05) between wild type and heterozygous Ikzf1 knock-
outs, where 5 mice from each group were compared (Table 3).
The empirical version of Hotelling’s test demonstrated global
significance (p = 0.03) of difference between distributions of IgG
glycome between wild type and Ikzf1 knock-out mice, where 5
mice from each group were compared. While the tests for
differences between individual glycome measurements did not
reach strict statistical significance after conservative Bonferroni
correction (p = 0.05/77 = 0.0006), we observed that 12 out of 77
(15%) IgG N-glycans measures showed nominally significant
difference (p,0.05) between wild type and heterozygous Ikzf1
knock-outs (Table 3). Significant results from the global
difference test ensure that difference between the two groups
does exist, and it is most likely due to the difference between (at
least some of) the measurements which demonstrated nominal
significance. Observed alterations in glycome composition were
all consistent with the role of IKZF1 in the down-regulation of
fucosylation and up-regulation of the addition of bisecting
GlcNAc to IgG glycans.
Investigating the biomarker potential of IgG N-glycans in
Systemic Lupus Erythematosus (SLE)
Given that IKZF1 has been convincingly associated with SLE in
previous studies [35–37], and that functional studies in heterozy-
gous knock-out mice in our study showed clear differences in
profiles of several IgG N-glycan traits, we explored an intriguing
hypothesis: whether the same IgG N-glycan traits that were
significantly affected in Ikzf1 knock-out mice could be demon-
strated to differ between human SLE cases and controls. If this
were true, then pleiotropy between the effects of IKZF1 on SLE
and on IgG N-glycans in human plasma, revealed by independent
GWA studies, would lead to a discovery of a novel class of
biomarkers of SLE – IgG N-glycans – which could possibly extend
their usefulness in prediction of other autoimmune disorders,
cancer and neuropsychiatric disorders, through the same mech-
anism.
To test this hypothesis, we measured IgG N-glycans in 101 SLE
cases and 183 matched controls (typically two controls per case),
recruited in Trinidad (see materials and methods for further
details). Table 4 shows the results of the measurements: for 10 of
12 N-glycan traits chosen on a basis of the experiments in mice
(Table 3). The entire dataset for all glycans can be found in Table
S8. There was a statistically significant difference (p,0.05)
between SLE cases and controls, which was generally not the
case with other groups of N-glycans (data not shown). Moreover,
Genetic Loci Affecting IgG Glycosylation
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the significance of the difference was striking in some cases, e.g.
p,10214 for IGP48, p,10213 for IGP8, and p,1026 for IGP64.
Furthermore, the differences in the direction of effect in mice were
strikingly preserved in humans (Table 4). The most significant
differences observed across all 77 IgG N-glycans measurements
between SLE cases and controls (Table 4) were overlapping well
with the 12 N-glycan groups that were significantly changed in
functional experiments in Ikzf1 knock-out mice.
To strengthen our findings and control for possible bias, we
repeated the analysis excluding all the cases on corticosteroid
treatment at the time of interview (77/101) and subsequently all
the cases that were not on corticosteroid treatment at the time of
interview (24/101). Although the power of the analysis decreased
due to reduced number of cases, the results did not change and
they remained highly statistically significant. We also hypothesized
that the observed glycan changes may not be specific to SLE, but
Table 3. Twelve groups of IgG N-glycans (of 77 measured) that showed nominally significant difference (p,0.05) in observed
values between 5 mice that were heterozygous Ikzf1 knock-outs (Neo) and 5 wild-type controls (wt).
Increased N-glycans
N-glycan group code N-glycan trait Mean (Neo) Mean (wt) Mean(Neo)/Mean(wt) p-value*
IGP8 GP9 - FA2[3]G1 8.91 7.44 1.20 3.54E-03
IGP48 GP9n – GP9/GPn*100 11.71 10.34 1.13 1.41E-02
IGP64 % FG1n/G1n 98.47 97.53 1.01 2.63E-02
Decreased N-glycans
N-glycan group code N-glycan trait Mean (Neo) Mean (wt) Mean(Neo)/Mean(wt) p-value*
IGP9 GP10 - FA2[6]BG1 0.13 0.17 0.76 2.32E-03
IGP10 GP11 - FA2[3]BG1 0.34 0.62 0.55 4.74E-02
IGP19 GP20 – (undetermined) 12.29 15.07 0.82 7.62E-03
IGP23 GP24 - FA2BG2S2 1.27 1.50 0.85 3.20E-02
IGP37 FBS1/FS1 0.12 0.18 0.67 4.93E-02
IGP38 FBS1/(FS1+FBS1) 0.10 0.15 0.67 4.84E-02
IGP49 GP10n – GP10/GPn*100 0.17 0.24 0.71 1.71E-03
IGP50 GP11n – GP11/GPn*100 0.44 0.87 0.51 4.27E-02
IGP68 % FBG1n/G1n 1.15 2.05 0.56 2.76E-02
The global difference test was significant (p = 0.03). *t-test for equality of means (2-tailed).
doi:10.1371/journal.pgen.1003225.t003
Table 4. Groups of IgG N-glycans from Table 3 that showed statistically significant difference in observed values (corrected by sex,
age, and African admixture) between 101 Afro-Caribbean cases with SLE and 183 controls.
Decreased N-glycans
N-glycan group code N-glycan trait Mean (SLE) Mean (controls) Mean(SLE)/Mean(controls) p-value*
IGP8 GP9 - FA2[3]G1 6.67 8.03 0.83 1.86E-14
IGP48 GP9n – GP9/GPn*100 9.09 11.06 0.82 6.72E-15
IGP64 % FG1n/G1n 80.93 83.22 0.97 5.07E-07
IGP19 GP20 – (undetermined) 0.73 0.80 0.91 4.87E-02
Increased N-glycans
N-glycan group code N-glycan trait Mean (SLE) Mean (controls) Mean(SLE)/Mean(controls) p-value*
IGP9 GP10 - FA2[6]BG1 4.58 4.13 1.10 4.37E-04
IGP23 GP24 - FA2BG2S2 3.00 2.65 1.13 1.67E-03
IGP37 FBS1/FS1 0.20 0.18 1.11 5.08E-03
IGP38 FBS1/(FS1+FBS1) 0.17 0.15 1.13 4.83E-03
IGP49 GP10n – GP10/GPn*100 6.24 5.70 1.09 1.39E-03
IGP68 % FBG1n/G1n 17.34 15.30 1.13 2.19E-06
*t-test for equality of means (2-tailed).
doi:10.1371/journal.pgen.1003225.t004
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may be caused by corticosteroid treatment, or secondary to any
inflammatory process. For this reason, and in SLE cases only, we
investigated whether corticosteroid treatments and/or CRP
measurements, were associated with IgG N-glycan traits. Analysis
for CRP was repeated with CRP treated as a binary variable (with
cut-off value at 10 mg/L). In all these analyses, the initial results
held and were not changed: the association of IgG N-glycans and
SLE remained striking, while the association with corticosteroid
treatment and CRP was not (Table S9). Finally, we also repeated
the analysis adjusting for percent African admixture, as it has been
reported that SLE in Afro-Caribbean population is associated with
African admixture [69]. However, this adjustment only had a
minor and non-systemic effect on the previous results, and the
reported observations remained.
We then validated biomarker potential of IGP48, the IgG N-
glycan trait most significantly associated with SLE status, in
prediction of SLE in 101cases and 183 matched controls. We used
the PredictABEL package for R (see materials and methods) [70].
As shown in Figure 3, age, sex and African admixture did not have
any predictive power for this disease, but addition of IGP48
substantially increased sensitivity and specificity of prediction, with
area under receiver-operator curve (AUC) increasing from 0.515
(95% confidence interval (CI): 0.441–0.590) to 0.842 (0.791–
0.893). It is likely that further additions of other IgG N-glycans
could provide even more accurate predictions. To cross-validate
this result, we split our dataset with SLE cases and controls into a
‘‘training set’’ (2/3; 67 cases and 122 controls) and ‘‘test set’’ (1/3;
34 cases and 61 controls). Area under ROC-curve (AUC) was
calculated for the test dataset. The whole process was repeated
1000 times, to allow computation of the mean AUC (and 95% CI)
in the test datasets. Mean AUC was virtually unchanged
compared to AUC obtained when using the complete dataset
and no training, which suggests that the predictive power of IGP48
on SLE is very robust.
Discussion
This study clearly demonstrates that the recent developments in
high-throughput glycomics and genomics now allow identification
of genetic loci that control N-glycosylation of a single plasma
protein using a GWAS approach. This progress should allow
many similar follow-up studies of genetic regulation of N-
glycosylation of other important plasma proteins, thus bringing
unprecedented insights into the role of protein glycosylation in
systems biology. As a prelude to this discovery, we recently
reported the results of the first GWA study of the overall human
plasma N-glycome using the HPLC method. Although the study
was of a comparable sample size (N,2000), it only identified
genome-wide associations with two glycosyltransferases and one
transcription factor (HNF1a) [71]. We believe that the power of
our initial study was reduced because N-glycans in human plasma
originate from different glycoproteins where they have different
functions and undergo protein-specific, or tissue-specific glycosyl-
ation. In this study the largest percentage of variance explained by
a single association was 16–18% where as in the N-glycan study
this was 1–6%. Furthermore, concentrations of individual
glycoproteins in plasma vary in many physiological processes,
introducing substantial ‘‘noise’’ to the quantitation of the whole-
plasma N-glycome.
In this study we avoided both problems by isolating a single
protein from plasma (IgG), which is produced by a single cell type
(B lymphocytes), thus effectively excluding differential regulation
of gene expression in different tissues, and the ‘‘noise’’ introduced
by variation in plasma IgG concentration and by N-glycans on
other plasma proteins. The only remaining ‘‘noise’’ in our system
was the incomplete separation of some glycan structures (which co-
eluted from the UPLC column) and the presence of Fab glycans on
a subset of IgG molecules, but for the majority of glycan structures
this ‘‘noise’’ was well below 10% [19]. We expected that the
specificity of our phenotype and precision of the measurement
provided by novel UPLC and MS methods should substantially
increase the power of the study to detect genome-wide associa-
tions. Prior to analysis we could not predict which quantitation
method would work better in GWA study design (UPLC vs. MS),
so we used them both, each in one separate cohort of comparable
sample size (N,2000).
The UPLC method yielded many more, and much stronger,
genome-wide association signals in comparison to our previous
study of the total plasma N-glycome in virtually same sample set of
examinees [27,71]. Sixteen loci were identified in association with
glycan traits with p-values,561028 and nine reached the strict
genome wide threshold of 2.2761029. The parallel study in the
LLS cohort using MS quantitation has independently identified
two of those 16 loci, showing genome-wide association with N-
glycan traits. MS quantitation also allowed us to replicate 6 further
loci identified in the discovery analysis, using comparable N-glycan
traits measured by the two methods. However, in this follow-up
analysis we were unable to replicate associations for the remaining
8 loci. This was not unexpected, because those glycosylation traits
correspond to different fucosylated glycans; since fucosylation was
not quantified by MS, the association between glycans measured
by MS and those regions should not be expected.
Among the nine loci that reached genome-wide statistical
significance, four involved genes encoding glycosyltransferases
known to glycosylate IgG (ST6GALI, B4GALT1, FUT8, MGAT3,).
The enzyme beta1,4-galactosyltransferase 1 is responsible for the
Figure 3. Validation of biomarker potential of IGP48 IgG N-
glycan percentage in prediction of Systemic Lupus Erythema-
tosus (SLE) in 101 Afro-Caribbean cases and 183 matched
controls. As shown in the graph, age and sex do not have any
predictive power for this disease, but addition of IGP48 substantially
increases sensitivity and specificity of prediction, with area under
receiver-operator curve increased to 0.828.
doi:10.1371/journal.pgen.1003225.g003
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addition of galactose to IgG glycans. Interestingly, variants in
B4GALT1 gene did not affect the main measures of IgG
galactosylation, but rather differences in sialylation and the
percentage of bisecting GlcNAc. These associations are still
biologically plausible, because galactosylation is a prerequisite
for sialylation, and enzymes which add galactose and bisecting
GlcNAc compete for the same substrate [72]. A potential
candidate for B4GALT1 regulator is IL6ST, which codes for
interleukin 6 signal transducer, because it showed stronger
associations with the main measures of IgG galactosylation than
B4GALT1 itself. Molecular mechanisms behind this association
remain elusive, but early work on IL6 (then called PHGF)
suggested that it may be relevant for glycosylation pathways in B
lymphocytes [73].
Core-fucosylation of IgG has been intensively studied due to its
role in antibody-dependent cell-mediated cytotoxicity (ADCC).
This mechanism of killing is considered to be one of the major
mechanisms of antibody-based therapeutics against tumours.
Core-fucose is critically important in this process, because IgGs
without core fucose on the Fc glycan have been found to have
ADCC activity enhanced by up to 100-fold [74]. Alpha-(1,6)-
fucosyltransferase (fucosyltransferase 8) catalyses the transfer of
fucose from GDP-fucose to N-linked type complex glycopeptides,
and is encoded by the FUT8 gene. We found that SNPs located
near this gene influenced overall levels of fucosylation. The
directly measured IgG glycome traits most strongly associated with
SNPs in the FUT8 region consisted of A2, and, less strongly, A2G1
and A2G2. These associations are biologically plausible as these
glycans serve as substrates for fucosyltransferase 8. Interestingly,
SNPs located near the IKZF1 gene influenced fucosylation of a
specific subset of glycans, especially those without bisecting
GlcNAc, and were also related to the ratio of fucosylated
structures with and without bisecting GlcNAc. This suggests the
IKZF1 gene encoding Ikaros as a potential indirect regulator of
fucosylation in B-lymphocytes by promoting the addition of
bisecting GlcNAc, which then inhibits fucosylation. The analysis of
IgG glycosylation in Ikzf1 haplodeficient mice confirmed the
postulated role of Ikaros in the regulation of IgG glycosylation
(Table 3). The effect of Ikzf1 haplodeficiency on IgG glycans
manifested mainly in the decrease in bisecting GlcNAc on different
glycan structures. The increase in fucose was observed only in a
subset of structures, but since very high level of fucosylation was
present in the wild type mouse (up to 99.8%), a further increase
could not have been demonstrated.
Nearly all genome-wide significant loci in our study have
already been clearly demonstrated to be associated with autoim-
mune diseases, haematologic cancers, and some of them also with
chronic inflammation and/or neuropsychiatric disorders. Al-
though the literature on those associations is extensive, we tried
to highlight only those associations that were identified using
genome-wide association studies in datasets independent from our
study. We gave prominence to associations arising from GWA
studies because they are typically replicable; GWA studies have
sufficient power to detect true associations, and require stringent
statistical testing and replication to avoid false positive results.
They have been reviewed and summarized in Table 2. The table
implies abundant pleiotropy between loci that control N-glycosyl-
ation (in this case, of IgG protein) and loci that have been
implicated in many human diseases. Autoimmune diseases
(including SLE, RA, UC and over 80 others) are generally
thought to be triggered by aggressive responses of the adaptive
immune system to self antigens, resulting in tissue damage and
pathological sequelae [38]. Among other mechanisms, IgG
autoantibodies are responsible for the chronic inflammation and
destruction of healthy tissues by cross-linking Fc receptors on
innate immune effector cells [75]. Class and glycosylation of IgG
are important for pathogenicity of autoantibodies in autoimmune
diseases (reviewed in [76]). Removal of IgG glycans leads to the
loss of the proinflammatory activity, suggesting that in vivo
modulation of antibody glycosylation might be a strategy to
interfere with autoimmune processes [75]. Indeed, the removal of
IgG glycans by injections of EndoS in vivo interfered with
autoantibody-mediated proinflammatory processes in a variety of
autoimmune models [75].
Results from our study suggest that IgG N-glycome composition
is regulated through a complex interplay between loci affecting an
overlapping spectrum of glycome measurements, and through
interaction of genes directly involved in glycosylation and those
that presumably have a ‘‘higher-level’’ regulatory function. SNPs
at several different loci in this GWA study showed genome-wide
significant associations with the same or similar IgG glycosylation
traits. For example, SNPs at loci on chromosomes 9 (B4GALT1
region) and 3 (ST6GAL1 region) both influenced the percentage of
sialylation of galactosylated fucosylated structures (without bisect-
ing GlcNAc) in the same direction. SNPs at these loci also
influenced the ratio of fucosylated monosialylated structures (with
and without bisecting GlcNAc) in the opposite direction. SNPs at
the locus on chromosome 9 (B4GALT1), and two loci on
chromosome 22 (MGAT3 and SMARCB1-DERL3 region) simulta-
neously influenced the ratio of fucosylated disialylated structures
with and without bisecting GlcNAc. SNPs at loci on chromosome
7 (IKZF1 region) and 14 (FUT8 region) influenced an overlapping
range of traits: percentage of A2 and A2G1 glycans, and, in the
opposite direction, the percentage of fucosylation of agalactosy-
lated structures.
Finally, this study demonstrated that findings from ‘‘hypothesis-
free’’ GWA studies, when targeted at a well defined biological
phenotype of unknown relevance to human health and disease
(such as N-glycans of a single plasma protein), can implicate
genomic loci that were not thought to influence protein
glycosylation. Moreover, unexpected pleiotropy of the implicated
loci that linked them to diseases has changed this study from
‘‘hypothesis-free’’ to ‘‘hypothesis-driven’’ [77], and led us to
explore biomarker potential of a very specific IgG N-glycan trait in
prediction of a specific disease (SLE) with considerable success. To
our knowledge, this is one of the first convincing demonstrations
that GWA studies can lead to biomarker discovery for human
disease. This study offers many additional opportunities to validate
the role of further N-glycan biomarkers for other diseases
implicated through pleiotropy.
Conclusions
A new understanding of the genetic regulation of IgG N-glycan
synthesis is emerging from this study. Enzymes directly responsible
for the addition of galactose, fucose and bisecting GlcNAc may not
have primary responsibility for the final IgG N-glycan structures.
For all three processes, genes that are not directly involved in
glycosylation showed the most significant associations: IL6ST-
ANKRD55 for galactosylation; IKZF1 for fucosylation; and
SMARCB1-DERL3 for the addition of bisecting GlcNAc. The
suggested higher-level regulation is also apparent from the
differences in IgG Fab and Fc glycosylation, observed in human
IgG [78,79] and different myeloma cell lines [80], and further
supported by recent observation that various external factors
exhibit specific effects on glycosylation of IgG produced in
cultured B lymphocytes [81].
Moreover, this study showed that it is possible to identify loci
that control glycosylation of a single plasma protein using a
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GWAS approach, and to develop a novel class of disease
biomarkers. This should lead to large advances in understanding
of the role of protein glycosylation in the future. This study
identified 16 genetic loci that are likely to be part of a much larger
genetic network that regulates the complex process of IgG N-
glycosylation and several further loci that show suggestive
association with glycan traits and merit further study. Genetic
variants in several of these genes were previously associated with a
number of inflammatory, neoplastic and neuropsychiatric diseases
across ethnically diverse populations, all of which could benefit
from earlier and more accurate diagnosis based on molecular
biomarkers. Variations in individual SNPs have relatively small
effects, but when several polymorphisms are combined in a
complex pathway like N-glycosylation, the final product of the
pathway - in this case IgG N-glycan - can be significantly different,
with consequences for IgG function and possibly also disease
susceptibility. Our results may also provide an explanation for the
reported pleiotropy and antagonistic genetic effects of loci involved
in autoimmune diseases and hematologic cancers [39,77].
Materials and Methods
Ethics statement
All research in this study that involved human participants has
been approved by the appropriate ethics committees: the Ethics
Committee of the University of Split Medical School for all
Croatian examinees from Vis and Korcula islands; the Local
Research Ethics Committees in Orkney and Aberdeen for the
Orkney Complex Disease Study (ORCADES); the University of
Uppsala (Dnr 2005:325) for all examinees from Northern Sweden;
the Leiden University Medical Centre Ethical Committee for all
participants in the Leiden Longevity Study (LLS); and the Ethics
Committee of the London School of Hygiene and Tropical
Medicine for all SLE cases and controls from Trinidad. All ethics
approvals were given in compliance with the Declaration of
Helsinki (World Medical Association, 2000). All human subjects
included in this study have signed appropriate informed consent.
Study participants—discovery and replication cohorts
All population studies recruited adult individuals within a
community irrespective of any specific phenotype. Fasting blood
samples were collected, biochemical and physiological measure-
ments taken and questionnaire data for medical history as well as
lifestyle and environmental exposures were collected following
similar protocols. Basic cohort descriptives are included in Table
S11.
The CROATIA-Vis study includes 1008 Croatians, aged 18–93
years, who were recruited from the villages of Vis and Komizˇa on
the Dalmatian island of Vis during 2003 and 2004 within a larger
genetic epidemiology program [82]. The CROATIA-Korcula
study includes 969 Croatians between the ages of 18 and 98 [83].
The field work was performed in 2007 and 2008 in the eastern
part of the island, targeting healthy volunteers from the town of
Korcˇula and the villages of Lumbarda, Zˇrnovo and Racˇisˇc´e.
The Orkney Complex Disease Study (ORCADES) was
performed in the Scottish archipelago of Orkney and collected
data between 2005 and 2011 [84]. Data for 889 participants aged
18 to 100 years from a subgroup of ten islands, were used for this
analysis.
The Northern Swedish Population Health Study (NSPHS) is a
family-based population study including a comprehensive health
investigation and collection of data on family structure, lifestyle,
diet, medical history and samples for laboratory analyses from
peoples living in the north of Sweden [84]. Complete data were
available from 179 participants aged 14 to 91 years.
DNA samples were genotyped according to the manufacturer’s
instructions on Illumina Infinium SNP bead microarrays (Hu-
manHap300v1 for CROATIA-Vis, HumanHap300v2 for OR-
CADES and NSPHS and HumanCNV370v1 for CROATIA-
Korcula). Genotypes were determined using Illumina BeadStudio
software. Genotyping was successfully completed on 991 individ-
uals from CROATIA-Vis, 953 from CROATIA-Korcula, 889
from ORCADES and 700 from NSPHS, providing a platform for
genome-wide association study of multiple quantitative traits in
these founder populations.
The Leiden Longevity Study (LLS) has been described in detail
previously [85]. It is a family based study and consists of 1671
offspring of 421 nonagenarian sibling pairs of Dutch descent, and
their 744 partners. 1848 individuals with available genotypic and
IgG measurements data were included in the current analysis.
Within the Leiden Longevity Study 1345 individuals were
genotyped using Illumina660 W (Rotterdam, Netherlands) and
503 individuals were genotyped using Illumina OmniExpress
(Estonian Biocentre, Genotyping Core Facility, Estonia).
Isolation of IgG and glycan analysis
In the discovery population cohorts (CROATIA-Vis, CROA-
TIA-Korcula, ORCADES, and NSPHS), the IgG was isolated
using protein G plates and its glycans analysed by UPLC in 2247
individuals, as reported previously [19]. Briefly, IgG glycans were
labelled with 2-AB fluorescent dye and separated by hydrophilic
interaction ultra-performance liquid chromatography (UPLC).
Glycans were separated into 24 chromatographic peaks and
quantified as relative contributions of individual peaks to the total
IgG glycome. The majority of peaks contained individual glycan
structures, while some contained more structures. Relative
intensities of each glycan structure in each UPLC peak were
determined by mass spectrometry as reported previously [19]. On
the basis of these 24 directly measured ‘‘glycan traits’’, additional
54 ‘‘derived traits’’ were calculated. These include the percentage
of galactosylation, fucosylation, sialylation, etc. described in the
Table S1. When UPLC peaks containing multiple traits were used
to calculate derived traits, only glycans with major contribution to
fluorescence intensity were used.
In the replication population cohort (Leiden Longevity Study),
the IgG was isolated from plasma samples of 1848 participants.
Glycosylation patterns of IgG1 and IgG2 were investigated by
analysis of tryptic glycopeptides using MALDI-TOF MS. Six
glycoforms per IgG subclass were determined by MALDI-
TOFMS. Since the intensities of all glycoforms were related to
the monogalactosylated, core-fucosylated biantennary species
(glycoform B), five relative intensities were registered per IgG
subclass [86].
Genotype and phenotype quality control
Genotyping quality control was performed using the same
procedures for all four discovery populations (CROATIA-Vis,
CROATIA-Korcula, ORCADES, and NSPHS). Individuals with
a call rate less than 97% were removed as well as SNPs with a call
rate less than 98% (95% for CROATIA-Vis), minor allele
frequency less than 0.02 or Hardy-Weinberg equilibrium p-value
less than 1610210. 924 individuals passed all quality control
thresholds from CROATIA-Vis, 898 from CROATIA-Korcula,
889 from ORCADES and 656 from NSPHS.
Extreme outliers (those with values more than 3 times the
interquartile distances away from either the 75th or the 25th
percentile values) were removed for each glycan measure to
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account for errors in quantification and to remove individuals not
representative of normal variation within the population. After
phenotype quality control the number of individuals with complete
phenotype and covariate information for the meta-analysis was
2247, consisting of 906 men and 1341 women (802 from
CROATIA-Vis, 851 from CROATIA-Korcula, 415 from OR-
CADES, 179 from NSPHS).
In Leiden Longevity Study, GenomeStudio was used for
genotyping calling algorithm. Sample call rate was .95%, and
SNP exclusions criteria were Hardy-Weinberg equilibrium p
value,1024, SNP call rate,95%, and minor allele frequency
,1%. The number of the overlapping SNPs that passed quality
controls in both samples was 296,619.
To combine the data from the different array sets and to
increase the overall coverage of the genome to up to 2.5 million
SNPs, we imputed autosomal SNPs reported in the Haplotype
Mapping Project (release #22, http://hapmap.ncbi.nlm.nih.gov)
CEU sample. Based on the SNPs that were genotyped in all arrays
and passed quality control, the imputation programmes MACH
(http://www.sph.umich.edu/csg/abecasis/MACH/) or IM-
PUTE2 (http://mathgen.stats.ox.ac.uk/impute/impute_v2.html)
were used to obtain ca. 2.5 million SNPs for further analysis.
For replication of genome-wide significant hits identified in the
discovery meta-analysis, all SNPs listed in Table S6 were used and
looked up in LLS. The only exception was rs11621121, which had
low imputation accuracy and did not pass quality control criteria.
For this SNP, a set of 11 proxy SNPs from HapMap r. 22 (all with
R2.0.85) was studied. All studied SNPs had imputation quality of
0.3 or greater.
Genome-wide association analysis
In the discovery populations, genome-wide association analysis
was firstly performed for each population and then combined using
an inverse-variance weighted meta-analysis for all traits. Each trait
was adjusted for sex, age and the first 3 principal components
obtained from the population-specific identity-by-state (IBS) derived
distances matrix. The residuals were transformed to ensure their
normal distribution using quantile normalisation. Sex-specific
analyses were adjusted for age and principal components only.
The residuals expressed as z-scores were used for association
analysis. The ‘‘mmscore’’ function of ProbABEL [87] was used for
the association test under an additive model. This score test for
family based association takes into account relationship structure and
allowed unbiased estimations of SNP allelic effect when relatedness is
present between examinees. The relationship matrix used in this
analysis was generated by the ‘‘ibs’’ function of GenABEL (using
weight = ‘‘freq’’ option), which uses genomic data to estimate the
realized pair-wise kinship coefficient. All lambda values for the
population-specific analyses were below 1.05 (Table S4), showing
that this method efficiently accounts for family structure.
Inverse-variance weighted meta-analysis was performed using the
MetABEL package (http://www.genabel.org) for R. SNPs with
poor imputation quality (R2,0.3) were excluded prior to meta-
analysis. Principal component analysis was performed using R to
determine the number of independent traits used for these analyses
(Table S10). 21 principal components explained 99% of the
variance so an association was considered statistically significant at
the genome-wide level if the p-value for an individual SNP was less
than 2.2761029 (561028/22 traits) [88]. SNPs were considered
strongly suggestive with p-values between 561028 and 2.2761029.
Regions of association were visualized using the web-based software
LocusZoom [89] to display the linkage disequilibrium (LD) of the
region based on hg18/1000 Genomes June 1010 CEU data. The
effect of the most significant SNP in each gene region expressed as
percentage of the variance explained was calculated for each glycan
trait adjusted for sex, age and first 3 principal components in each
cohort individually using the ‘‘polygenic’’ function of the GenABEL
package for R. Conditional analysis was undertaken for all
significant and suggestive regions. GWAS was performed as
described above with the additional adjustment for the dosage of
the top SNP in the region for only the chromosome containing the
association. Subsequent meta-analysis was performed as described
previously and the results visualised using LocusZoom to ensure that
the association peak have been removed.
In LLS, all IgG measurements were log-transformed. The score
statistic for testing for an additive effect of a diallelic locus on
quantitative phenotype was used. To account for relatedness in
offspring data we used the kinship coefficients matrix when
computing the variance of the score statistic. Imputation was dealt
with by accounting for loss of information due to genotype
uncertainty [90]. For the association analysis of the GWAS data,
we applied the score test for the quantitative trait correcting for sex
and age using an executable C++ program QTassoc (http://www.
lumc.nl/uh, under GWAS Software). For further details we refer
to supplementary online information.
Experiments in Ikzf1 knockout mice
The Ikzf1+/2 mice harbouring the Neo-PAX5-IRES-GFP knock
in allele were obtained from Meinrad Busslinger (IMP, Vienna) and
backcrossed to C57BL/6 mice. Both wild-type and Ikzf1Neo+/2
animals at the age of about 8 months were subjected to retro-orbital
puncture to collect blood in the presence of EDTA. Samples were
centrifuged for 10 minutes at room temperature and plasma was
harvested. IgG was isolated and subjected to glycan analyses.
Statistical significance of the difference in distributions of IgG
glycome between wild type and the Ikzf1+/2 mice was assessed
using empirical version of the Hotelling’s test. In brief, the
empirical distribution of the Hotelling’s T2 statistics was worked
out by permuting the group status of the animals at random
without replacement 10,000 times. This empirical distribution was
then contrasted with the original value of T2, with the proportion
of empirically observed T2 values greater than or equal to the
original T2 regarded as the empirical p-value.
Dataset with SLE cases and matched controls
A total of 101 SLE cases and 183 controls from Trinidad were
studied. The inclusion criteria for cases and controls in Trinidad
were designed to restrict the sample to individuals without Indian
or Chinese ancestry. Cases and controls were eligible to be
included if they were resident in northern Trinidad (excluding the
southern part of the island where Indians are in the majority) and
they had Christian (rather than Hindu, Muslim or Chinese) first
names. Identification of cases was carried out by contacting all
physicians specializing in rheumatology, nephrology and derma-
tology at the two main public hospitals in northern Trinidad and
asking for a list of all SLE patients from their out-patient clinics. At
the main dermatology clinic a register of cases since 1992 was
available. Furthermore, a systematic search of: (a) outpatient
records at the two hospitals, (b) hospital laboratory test results
positive for auto-antibodies (anti-nuclear or anti-double-stranded
DNA antibody titre .1:256) and (c) histological reports of skin
biopsy examination consistent with SLE was performed. Lastly,
SLE cases were also identified through the Lupus Society of
Trinidad and Tobago (90% of those patients were also identified
through one of the two main public hospitals). For each case,
randomly chosen households in the same neighbourhood were
sampled by the field team to obtain (where possible) two controls,
matched with the case for sex and for 20-year age group. Cases
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and controls were interviewed at home or in the project office by
using a custom made questionnaire.
The case definition of SLE was based on American Rheuma-
tism Association (ARA) criteria [91], applied to medical records
(available for more than 90% of cases), and to the medical history
given by the patient. Informed consent for blood sampling and the
use of the sample for genetic studies including estimation of
admixture was obtained from each participant. Initial case
ascertainment identified 264 possible cases of SLE. Of these, 72
(27%) were excluded either on the basis of their names or because
their medical history did not meet ARA criteria for the diagnosis of
SLE. Of the remaining 192 individuals, 54 had incomplete
addresses or were not resident in northern Trinidad, four were too
ill to be interviewed, eight were aged less than 18 years and two
refused to participate. For 80% (99/124) of cases, two matched
controls were obtained: the response rate from those invited to
participate as controls was 70%. The total sample consisted of 124
cases and 219 controls aged over 20 years who completed the
questionnaire. Blood samples were obtained from 122 cases and
219 controls and DNA was successfully extracted from 93% (317/
341) of these. IgG glycans were successfully measured in 303
individuals. Age at sampling was not available for 17 individuals
and 2 individuals were lost due to the ID mismatch.
To test predictive power of selected glycan trait, we fitted
logistic regression models (including and excluding the glycan) and
used predRisk function of PredictABEL package for R to evaluate
the predictive ability.
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